Distribution in Brain Areas of Carbamazepine and Carbamazepine-10,11-epoxide in 6-Hydroxydopamine Pretreated Rats

  • C. Pantarotto
  • V. Crunelli
  • A. Quattrone
  • P. Negrini
  • A. Frigerio
  • R. Samanin


Brain monoamines may be involved not only in the electroconvulsive threshold but also in the anticonvulsant activity of antiepileptic drugs in laboratory animals. Increased susceptibility to electroconvulsions has been reported in mice and rats treated with drugs which deplete brain monoamines, such as reserpine, a-methylparatyrosine and parachlorophenylalanine (1–4). These findings, together with reports on the anticonvulsant activity of two amine precursors, 1-dopa and 5-hydroxytryptophan (4, 5), and d-amphetamine (3), have led to the suggestion that brain monoamines may play a role in seizure susceptibility


Anticonvulsant Activity Anticonvulsant Effect Median Raphe Seizure Susceptibility Brain Monoamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    G. Chen, C.R. Ensor and B. Bohner, Proc. Soc. exp. Biol. Med., 1954, 86, 507.Google Scholar
  2. 2).
    B.K. Koe and A. Weissman, Adv. Pharmac., 1968, 6B, 29.CrossRefGoogle Scholar
  3. 3).
    A.D. Rudzik and G.A. Johnson, in “Amphetamines and Related Compounds”, E. Costa and S. Garattini, Eds., Raven Press, New York, 1970, p. 715.Google Scholar
  4. 4).
    M. Kilian and H.-H. Frey, Neuropharmac., 1973, 1 2, 681.Google Scholar
  5. 5).
    G. Chen, C.R. Ensor and B. Bohner, Arch. int. Pharmacodyn. ther., 1968, 172, 183.Google Scholar
  6. 6).
    H. Meyer and H.-H. Frey, Neuropharmac., 1973, 12 , 939.CrossRefGoogle Scholar
  7. 7).
    H.-H. Frey and M.P. Magnussen, Pharmacology, 1971, 5, 1.CrossRefGoogle Scholar
  8. 8).
    R.M. Julien and R.P. Hollister, in “Advances in Neurology”, Vol. 11, J.K. Penry and D.D. Daly, Eds., Raven Press, New York, 1975, p. 263.Google Scholar
  9. 9).
    N.J. Uretsky and L.L. Iversen, J. Neurochem., 1970, 17, 269.CrossRefGoogle Scholar
  10. 10).
    R. Samanin, D. Ghezzi, L. Valzelli and S. Garattini, Eur. J. Pharmac., 1972, 19, 318.CrossRefGoogle Scholar
  11. 11).
    G.R. Breese and T.D. Traylor, Br. J. Pharmac., 1971, 42, 88.Google Scholar
  12. 12).
    A.W. Kimball, W.T. Jr. Burnett and D.G. Doherty, Radiat. Res., 1957, 7. 1.CrossRefGoogle Scholar
  13. 13).
    A. Frigerio, F. Fanelli, P. Biandrate, G. Passerini, P.L. Morselli and S. Garattini, J. Pharm. Sci., 1972, 61, 1144.CrossRefGoogle Scholar
  14. 14).
    G. Belvedere, C. Pantarotto and A. Frigerio, Res. Commun. Chem. Pathol. Pharmacol., 1975, 11, 221.Google Scholar
  15. 15).
    A. Frigerio and P.L. Morselli, in “Advances in Neurology”, Vol. 11, J.K. Penry and D.D. Daly, Eds., Raven Press, New York, 1975, p. 295.Google Scholar
  16. 16).
    A. Frigerio and C. Pantarotto, in “Mass Spectrometry in Drug Metabolism”, A. Frigerio and E.L. Ghisalberti, Eds., Plenum Press, New York, 1977, p. 251.Google Scholar
  17. 17).
    K.M. Baker, A. Frigerio, P.L. Morselli and G. Pifferi, J. Pharm. Sci., 1973, 62, 475.CrossRefGoogle Scholar
  18. 18).
    C. Pantarotto, V. Crunelli, J. Lanzoni, A. Frigerio and A. Quattrone, Anal. Biochem., 1977, in pressGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • C. Pantarotto
    • 1
  • V. Crunelli
    • 1
  • A. Quattrone
    • 1
  • P. Negrini
    • 1
  • A. Frigerio
    • 1
  • R. Samanin
    • 1
  1. 1.Istituto di Ricerche Farmacologiche “Mario NegriVia EritreaItaly

Personalised recommendations